RE:RE:Not a bad call from Desjardins' Newmanprophetoffact wrote: MrMugsy wrote: Newman is calling for CareRx to generate fourth quarter revenue of $91.2 million (actual was $96.9M) and adjusted EBITDA of $8.0 million (actual of $7.6M, exclude non-occurring would be $8.7M).
Those are very strong results and CRRX beat revenue expetations of an average of nine analysts who have an average target price of $9.03. Should be some strong buys coming out given the very strong adjusted EBITDA of $8.7 with more to come with facility consolidation and the new equipment.
Yes - agreed !!!
Here's what I like going forward ...
1. largest sales team in the country (in this space).
2. strategic acquisitions are in focus (smaller - but that's still good).
3. organic growth is also a driver - and - see #1 above.
4. Revicare products will be using the same trucks as used for medications - very efficient.
5. Murphy has some experience in products like Revicare which should make our strategy that much more effective - been there, done that !!!
6. Remaking our fulfillment sites (as you said).
7. Goal in place to expand margin from 9% to 12%.
All were discussed (or mentioned) in the conference call.
In my opinion ... the real victory is in one's ability to wait for the future sale of this company - when it's a fully developed national entity. That's when you make the money. Question is ... who can wait it out? Many take the early or quick win because they just can't go the distance. It's a tough mental game.
Good Luck All !